EXHIBIT 99.5
Published on May 30, 2013
EXHIBIT 99.5
|
KPMG LLP
600 de Maisonneuve Blvd. West
Suite 1500
Tour KPMG
Montréal, Québec H3A 0A3
|
Telephone (514) 840-2100
Fax (514) 840-2187
Internet www.kpmg.ca
|
Consent of Independent Auditors
The Board of Directors
Acasti Pharma Inc.
We consent to the use of our report dated May 21, 2013 with respect to the financial statements of Acasti Pharma Inc. (the “Company”), which comprise the statements of financial position as at February 28, 2013 and February 29, 2012, the statements of earnings and comprehensive loss, changes in equity and cash flows for the years then ended and notes, comprising a summary of significant accounting policies and other explanatory information, included in this annual report on Form 40-F of the Company. Our report contains an emphasis of matter paragraph that states that the Company has incurred operating losses and negative cash flows from operations since inception, and the existence of a material uncertainty that casts substantial doubt about the Company’s ability to continue as a going concern.
May 29, 2013
Montreal, Canada
*CPA, auditor, CA, public accountancy permit No. A110592
|
KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG
network of independent member firms affiliated with KPMG International Cooperative
(“KPMG International”), a Swiss entity. KPMG Canada provides services to KPMG LLP.
|